Pfizer (PFE) : Integrated Investment Consultants scooped up 400 additional shares in Pfizer during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 12, 2016. The investment management firm now holds a total of 41,205 shares of Pfizer which is valued at $1,339,163.Pfizer makes up approximately 0.76% of Integrated Investment Consultants’s portfolio.
Pfizer closed down -0.15 points or -0.46% at $32.5 with 3,52,74,322 shares getting traded on Friday. Post opening the session at $32.65, the shares hit an intraday low of $32.3 and an intraday high of $32.785 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
Other Hedge Funds, Including , Banced Corp boosted its stake in PFE in the latest quarter, The investment management firm added 2,813 additional shares and now holds a total of 11,269 shares of Pfizer which is valued at $366,243. Pfizer makes up approx 0.64% of Banced Corp’s portfolio.Abner Herrman Brock boosted its stake in PFE in the latest quarter, The investment management firm added 98,050 additional shares and now holds a total of 391,987 shares of Pfizer which is valued at $12,500,465. Pfizer makes up approx 3.17% of Abner Herrman Brock’s portfolio.Partnerre Asset Management Corp reduced its stake in PFE by selling 700 shares or 1.68% in the most recent quarter. The Hedge Fund company now holds 40,927 shares of PFE which is valued at $1,305,162. Pfizer makes up approx 0.70% of Partnerre Asset Management Corp’s portfolio.Sunnymeath Asset Management reduced its stake in PFE by selling 7,590 shares or 14.49% in the most recent quarter. The Hedge Fund company now holds 44,803 shares of PFE which is valued at $1,428,768. Pfizer makes up approx 2.23% of Sunnymeath Asset Management’s portfolio.Nadler Financial Group boosted its stake in PFE in the latest quarter, The investment management firm added 27 additional shares and now holds a total of 29,661 shares of Pfizer which is valued at $945,889. Pfizer makes up approx 0.42% of Nadler Financial Group’s portfolio.
On the company’s financial health, Pfizer reported $0.53 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on Feb 2, 2016. Analyst had a consensus of $0.36. The company had revenue of $14047.00 million for the quarter, compared to analysts expectations of $13595.19 million. The company’s revenue was up 7.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.54 EPS.
Many Wall Street Analysts have commented on Pfizer. Goldman Resumed Pfizer on Apr 18, 2016 to “Neutral”, Price Target of the shares are set at $35.JP Morgan Resumed Pfizer on Apr 7, 2016 to “Overweight”, Price Target of the shares are set at $38.Morgan Stanley Resumed Pfizer on Apr 7, 2016 to “Equal-Weight”, Price Target of the shares are set at $35.
Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.